Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Privia Health Group Inc tiene un precio objetivo de consenso de $29.54 basado en las calificaciones de 26 analistas. El máximo es $41, emitido por Credit Suisse el junio 22, 2023. El mínimo es $21, emitido por B of A Securities el febrero 22, 2024. Las 3 calificaciones de analistas más recientes fueron publicadas por JP Morgan, BMO Capital y Canaccord Genuity el noviembre 13, 2025, noviembre 13, 2025 y noviembre 12, 2025, respectivamente. Con un precio objetivo promedio de $32.33 entre JP Morgan, BMO Capital y Canaccord Genuity, hay una 36.20% upside implícita para Privia Health Group Inc según estas calificaciones más recientes de analistas.
1calculado a partir de las calificaciones de los analistas
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
11/13/2025 | 39.01% | JP Morgan | $32 → $33 | Maintains | Overweight | |||
11/13/2025 | 26.37% | BMO Capital | → $30 | Initiates | → Outperform | |||
11/12/2025 | 43.22% | Canaccord Genuity | $32 → $34 | Maintains | Buy | |||
11/10/2025 | -3.12% | Barclays | $22 → $23 | Maintains | Equal-Weight | |||
11/10/2025 | 30.58% | Truist Securities | $30 → $31 | Reiterates | Buy → Buy | |||
11/07/2025 | 26.37% | Evercore ISI Group | $28 → $30 | Maintains | Outperform | |||
11/07/2025 | 30.58% | Citizens | $30 → $31 | Maintains | Market Outperform | |||
10/09/2025 | -7.33% | Barclays | $21 → $22 | Maintains | Equal-Weight | |||
09/24/2025 | 34.79% | Stephens & Co. | $32 → $32 | Reiterates | Overweight → Overweight | |||
09/04/2025 | 34.79% | Stephens & Co. | $32 → $32 | Reiterates | Overweight → Overweight | |||
08/29/2025 | 26.37% | JMP Securities | $29 → $30 | Maintains | Market Outperform | |||
08/11/2025 | 47.43% | Piper Sandler | $36 → $35 | Maintains | Overweight | |||
07/09/2025 | 17.94% | Evercore ISI Group | $30 → $28 | Maintains | Outperform | |||
05/28/2025 | 34.79% | JP Morgan | $29 → $32 | Maintains | Overweight | |||
05/27/2025 | 1.1% | Barclays | $23 → $24 | Maintains | Equal-Weight | |||
04/28/2025 | 22.16% | JMP Securities | $29 → $29 | Reiterates | Market Outperform → Market Outperform | |||
04/15/2025 | 9.52% | Baird | $24 → $26 | Maintains | Outperform | |||
04/10/2025 | -3.12% | Barclays | $21 → $23 | Maintains | Equal-Weight | |||
04/10/2025 | 17.94% | Truist Securities | $27 → $28 | Maintains | Buy | |||
04/10/2025 | 26.37% | Needham | $30 → $30 | Reiterates | Buy → Buy | |||
03/21/2025 | 26.37% | Needham | $30 → $30 | Reiterates | Buy → Buy | |||
02/28/2025 | 22.16% | Citizens Capital Markets | $26 → $29 | Maintains | Market Outperform | |||
02/28/2025 | 26.37% | Canaccord Genuity | $29 → $30 | Maintains | Buy | |||
02/28/2025 | 68.49% | Piper Sandler | $25 → $40 | Maintains | Overweight | |||
02/28/2025 | 26.37% | Needham | $25 → $30 | Maintains | Buy | |||
02/14/2025 | 9.52% | JMP Securities | $26 → $26 | Maintains | Market Outperform | |||
01/15/2025 | 5.31% | Needham | $25 → $25 | Reiterates | Buy → Buy | |||
01/10/2025 | 5.31% | Needham | → $25 | Initiates | → Buy | |||
01/07/2025 | 9.52% | Stephens & Co. | $26 → $26 | Reiterates | Overweight → Overweight | |||
01/02/2025 | 9.52% | Stephens & Co. | $26 → $26 | Reiterates | Overweight → Overweight | |||
12/16/2024 | 5.31% | Macquarie | → $25 | Initiates | → Outperform | |||
11/29/2024 | 17.94% | JP Morgan | $27 → $28 | Maintains | Overweight | |||
11/08/2024 | -11.54% | Barclays | $19 → $21 | Maintains | Equal-Weight | |||
11/08/2024 | 13.73% | Truist Securities | $24 → $27 | Maintains | Buy | |||
10/11/2024 | -3.12% | Keybanc | → $23 | Initiates | → Overweight | |||
08/26/2024 | 1.1% | Baird | $23 → $24 | Maintains | Outperform | |||
08/14/2024 | 17.94% | RBC Capital | $28 → $28 | Reiterates | Outperform → Outperform | |||
07/09/2024 | -15.75% | Evercore ISI Group | $23 → $20 | Maintains | Outperform | |||
05/30/2024 | -3.12% | Baird | → $23 | Initiates | → Outperform | |||
05/20/2024 | -19.97% | Barclays | $22 → $19 | Maintains | Equal-Weight | |||
05/15/2024 | 1.1% | Truist Securities | $28 → $24 | Maintains | Buy | |||
05/10/2024 | 9.52% | Canaccord Genuity | $37 → $26 | Maintains | Buy | |||
05/01/2024 | 1.1% | Stifel | $28 → $24 | Maintains | Buy | |||
04/22/2024 | 5.31% | Citigroup | → $25 | Initiates | → Buy | |||
03/19/2024 | 55.86% | Canaccord Genuity | $41 → $37 | Maintains | Buy | |||
03/06/2024 | 26.37% | JP Morgan | $38 → $30 | Maintains | Overweight | |||
03/06/2024 | -7.33% | Barclays | → $22 | Initiates | → Equal-Weight | |||
03/01/2024 | 22.16% | UBS | $31 → $29 | Maintains | Buy | |||
03/01/2024 | 9.52% | TD Cowen | $30 → $26 | Maintains | Outperform | |||
02/29/2024 | 17.94% | Truist Securities | $32 → $28 | Maintains | Buy | |||
02/28/2024 | 5.31% | Evercore ISI Group | $26 → $25 | Maintains | Outperform | |||
02/22/2024 | -11.54% | B of A Securities | $27 → $21 | Downgrade | Buy → Neutral | |||
12/06/2023 | 13.73% | JMP Securities | → $27 | Initiates | → Market Outperform | |||
11/17/2023 | 60.07% | JP Morgan | $43 → $38 | Maintains | Overweight | |||
08/18/2023 | 34.79% | UBS | $35 → $32 | Maintains | Buy | |||
08/15/2023 | 47.43% | TD Cowen | $44 → $35 | Maintains | Outperform | |||
06/22/2023 | 72.7% | Credit Suisse | → $41 | Reiterates | Outperform → Outperform | |||
06/13/2023 | 43.22% | Evercore ISI Group | → $34 | Initiates | → Outperform | |||
05/08/2023 | 72.7% | Credit Suisse | → $41 | Reiterates | → Outperform | |||
04/12/2023 | 39.01% | Stephens & Co. | → $33 | Initiates | → Overweight | |||
03/10/2023 | 51.64% | RBC Capital | → $36 | Initiates | → Outperform | |||
03/07/2023 | 72.7% | Credit Suisse | → $41 | Reiterates | → Outperform | |||
02/03/2023 | 34.79% | Goldman Sachs | → $32 | Initiates | → Buy | |||
12/09/2022 | 17.94% | Stifel | → $28 | Initiates | → Buy | |||
12/08/2022 | 26.37% | UBS | → $30 | Initiates | → Buy |
El último precio objetivo de Privia Health Gr (NASDAQ:PRVA) fue comunicado por JP Morgan el noviembre 13, 2025. La firma de analistas fijó un precio objetivo para $33.00 que espera PRVA a rise dentro de 12 meses (un posible 39.01% upside). 32 firmas de analistas han reportado calificaciones en el último año.
La última calificación de analistas para Privia Health Gr (NASDAQ:PRVA) fue proporcionada por JP Morgan, y Privia Health Gr mantuvo su overweight calificación.
No hay última actualización para Privia Health Gr
La última revisión a la baja de Privia Health Group Inc se produjo en febrero 22, 2024, cuando B of A Securities cambió su precio objetivo de $27 a $21 para Privia Health Group Inc.
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Privia Health Gr, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Privia Health Gr se registró el noviembre 13, 2025, por lo que la próxima calificación estará disponible en torno al noviembre 13, 2026.
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Privia Health Gr (PRVA) fue un mantuvo con un precio objetivo de $32.00 a $33.00. El precio actual al que cotiza Privia Health Gr (PRVA) es de $23.74, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.